Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|February 1, 2022

BioPharm International

  • BioPharm International, February 2022
  • Volume 35
  • Issue 2
  • Pages: 40

Sustainable Biowaste Treatment System

The MicroEDS BioWaste Treatment System can process between 150 to 500 L of waster per day.

Suncombe’s MicroEDS BioWaste Treatment System is a biologically hazardous waste decontamination unit that can process between 150 to 500 L of waste per day. The low-volume system is certified to ASME and ISO/EN standards for treating biosafety level 1, 2, and 3 waste through an innovative batch process that allows for the positive release of all collected waste.

Advances in the MicroEDS include thermal energy regeneration, low energy usage, and 100% positive release for treated waste and electronic records generation. The system is designed to operate at a thermal treatment parameter of 121 °C for 15 minutes, as well as variable temperature, time and f0 lethality settings, for specific requirements.

According to Suncombe, the new unit delivers at least 61% energy saving relative to prior models and can reduce energy usage and utility consumption by up to 75%. Additionally, based on average use, it reduces the carbon footprint by up to 1.68 tons of carbon dioxide each year.

Suncombe www.suncombe.eu

Articles in this issue


Related to this article

The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.
The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.